Clinical Research Directory

Inclusion Criteria: * Adult patients with SARS-CoV-2 in France, treated in a center participating in the study * Symptomatic patients for Covid-19 who have received mono- or dual therapy with nirmatrelvir/ritonavir or remdesivir * SARS-CoV-2 positive by PCR on nasopharyngeal swab, ECBC or bronchoalveolar fluid * Hospitalization in a ward or day hospital for SARS-CoV-2 infection * Patients at very high risk of severe form of SARS-CoV-2 * Aggressive lymphomas (all types) * Acute lymphocytic leukemia * Acute myeloid leukemia * Acute promyelocytic leukemia * T-cell prolymphocytic leukemia * Primary lymphoma of the central nervous system * Stem cell transplant * Light chain amyloidosis * Chronic lymphocytic leukemia * Multiple myeloma * Hematopoietic stem cell transplant * Solid organ transplant * Being on the waiting list for an organ transplant * Primary immunodeficiency; * HIV patients with CD4 \<200/mm3 or with a detectable viral load * Lymphopenia \<200/mm3 * Neutropenia \<1000/mm3 for \> 1 week * Patients receiving long-term immunosuppressive treatment (period of at least 3 months during treatment during infection) with: * anti-CD20 antibodies * anti-JAK * BTK inhibitors * azathioprine * cyclophosphamide * methotrexate * mycophenolate mofetil * CAR-T cell gene therapy * bi-phenotypic therapeutic antibodies * tacrolimus * sirolimus * long-term corticosteroids (prednisone equivalent dose \>5mg for 3 months) Exclusion Criteria: * Opposition formulated (following receipt of the study information note) * Patients who received convalescent plasma as first-line treatment for SARS-CoV-2 infection